166 related articles for article (PubMed ID: 9205748)
1. Pharmacokinetics of ebrotidine in rats and dogs.
Albet C; Pérez JA; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[TBL] [Abstract][Full Text] [Related]
5. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
6. Acute toxicity studies of ebrotidine.
Grau MT; Romero A; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):490-1. PubMed ID: 9205750
[TBL] [Abstract][Full Text] [Related]
7. Subacute toxicity of ebrotidine in rats and dogs.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):492-7. PubMed ID: 9205751
[TBL] [Abstract][Full Text] [Related]
8. Chronic toxicity of ebrotidine in rats and dogs.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Romero A; Gómez F; Villamayor F; Ballesta A; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
[TBL] [Abstract][Full Text] [Related]
10. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[TBL] [Abstract][Full Text] [Related]
11. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
12. Carcinogenicity studies on ebrotidine.
Romero A; Rives A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):515-9. PubMed ID: 9205755
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
[TBL] [Abstract][Full Text] [Related]
14. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys.
Maeshiba Y; Kiyota Y; Yamashita K; Yoshimura Y; Motohashi M; Tanayama S
Arzneimittelforschung; 1997 Jan; 47(1):29-35. PubMed ID: 9037440
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of famotidine in man.
Kroemer H; Klotz U
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
[TBL] [Abstract][Full Text] [Related]
17. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Palop D; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
[TBL] [Abstract][Full Text] [Related]
20. Study of the population of antral G-cells and enterochromaffin-like cells in the rat and mouse gastric mucosa after long-term treatment with ebrotidine.
Romero A; Gómez F; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):520-3. PubMed ID: 9205756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]